Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/25/2005 First Published: 11/1/1992


1.		Phase III Randomized Trial of Strontium-89 vs Palliative Local Radiotherapy in Patients with Hormone-Refractory Prostate Cancer with Painful Osseous Metastases (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								EORTC-30921 NCT00002503

Last Modified: 9/21/2007


2.		Phase I/II Study of Strontium-89 in the Treatment of Patients with Endocrine-Resistant Prostate Cancer with Painful Osseous Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Completed				any age				NCI				RTOG-8821 RTOG-88-21

Last Modified: 2/1/1999


3.		Phase II Randomized Study of Strontium-89 Alone, Estramustine/Vinblastine, and Strontium-89 plus Estramustine/Vinblastine in Androgen-Independent Prostate Cancer Metastatic to Bone (Summary Last Modified 02/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				MSKCC-95094 NCI-V96-0831

Last Modified: 8/1/1999 First Published: 12/1/1997


4.		Phase II Study of Sn-117m DTPA versus Strontium-89 in Patients with Painful Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				18 and over				Pharmaceutical / Industry				DIATIDE-117-30 UCMC-97012201

Last Modified: 4/17/2007 First Published: 3/24/2004


5.		Phase II Randomized Study of Doxorubicin and Strontium Chloride Sr 89 With or Without Celecoxib in Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Any age				NCI				MDA-ID-02035 NCT00080782

Last Modified: 11/12/2007 First Published: 3/24/2004


6.		Phase II Randomized Study of Hormonal Ablative Therapy, Doxorubicin, and Zoledronate With or Without Strontium Chloride Sr 89 in Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				NCI				MDA-2003-0922 6459, NCI-6459, NCT00081159


7.		A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				GUPPS2 NCT00156884

Select All on One Page